Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India

Interdisciplinary Toxicology

Volumn 6, Issue 1, 2013, Pages 41-46

  Patidar, Dindayal ^a   Rajput, Mithun S ^b   Nirmal, Nilesh P ^c   Savitri, Wenny ^c  

^a SGI   (India)

^b IPS Academy   (India)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Adverse drug reaction; Hospital based monitoring; Pharmacovigilance; Questionnaire survey

Indexed keywords

ANTIBIOTIC AGENT; ANTIGOUT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TUBERCULOSTATIC AGENT;

ADVERSE DRUG REACTION; ADVERSE DRUG REACTION MONITORING; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DIZZINESS; DRUG COMBINATION; DRUG EXPOSURE; EVALUATION STUDY; FEMALE; GASTRITIS; HEALTH CARE PLANNING; HUMAN; HYPOTENSION; INDIA; MALE; MONITORING; MORBIDITY; MORTALITY; PHYSICIAN; PROSPECTIVE STUDY; PRURITUS; RASH; RATING SCALE; SHIVERING; STEVENS JOHNSON SYNDROME; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TRAINING; URTICARIA;

EID: 84892539948     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.2478/intox-2013-0008     Document Type: Article

References (27)

1. Bates DW, Spell N, Cullen DJ. (1997). The costs of adverse drug reactions in hospitalised patients. JAMA 277: 301-307.
2. Bergman US. Wilholm BF. (1981). Drug related problems causing admission to a medical clinic. Eur J Clin Pharmacol 20: 193-200.
3. Bremnan T, Leape L, Iared N. (1991). Incidence of adverse events and negligence in hospitalised patients. New Eng J Med 324: 370-376.
4. Caranasos GJ, Stewart RB, Cluff LE. (1974). Drug induced illness leading to hospitalization. JAMA 228: 713-717.
5. Coelo HL, Arrais PS.D, Parente AP, Brizeno MOB. (2002). Federal University of Ceaara, Fortaleza, Brazil. Pharmacoepidemiol Drug Safety 11(Suppl 2): S231-S294.
6. Cohen JS. (1999). Ways to minimize ADRs- Individualised doses and common sense are key. J Postgrad Med 106: 163-172.
7. Coulter DM. (2002). Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach. Drug Saf 25: 433-439.
8. Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S, et al. (2003). Lack of awareness of community-acquired adverse drug reactions upon hospital admission. Drug Saf 26: 353-362.
9. Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BH. (1999). Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol 48: 623-627.
10. Hartwig S, Siegel J, Schneider P. (1992). Preventability and severity assessment in reporting adverse drug reactions. American J Hosp Pharm 49: 2229-2232.
11. Leape LL. (1994). Errors in medicine. JAMA 272: 1851-1857.
12. Levy M, Azaz-Livshits T, Sudan B, Shalit M, Geisslinger G, Brune K. (1999). Computerized surveillance of adverse drug reactions in hospital: Implementation. Eur J Clin Pharmacol 54: 887-892.
13. Lin SH, Lin MS. (1991). A survey on drug related hospitalization in a community teaching hospital. Int Clin Pharmacol Ther Toxicol 31: 66-69.
14. MCA/CSM. (2000). Cisparide (Prepulsid) withdrawn. Current Prob Pharmacovigilance 26: 9-10.
15. Meyboom RH, Linquist M, Egberts AC, Edward IR. (2002). Signal selection and follow-up in pharmacovigilance. Drug Saf 25: 459-465.
16. Murphy BM, Frigo LC. (1993). Development, implementation and results of a successful multidisciplinary adverse drug reaction reporting program in university teaching hospital. Hosp Pharm 28: 1199-1204.
17. Naranjo C, Shear N, Lanctot K. (1992). Advances in the diagnosis of Adverse Drug Reactions. J Clin Pharmacol 32: 897-904.
18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. (1981). A method of assessing the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245.
19. Pirmohamed M, Breckenridge AM, Kitterinham NR, Park BK. (1998). Fortnightly review: adverse drug reactions. BMJ 316: 1295-1298.
20. Rajesh R, Ramesh M, Parthasarathi G. (2008). A study on adverse drug reactions related hospital admission and their management. Indian J Hospial Pharm 45: 143-148.
21. Schumock GT, Seeger JD, Kong SX. (1995). Control charts to monitor rates of adverse drug reactions. Hosp Pharm 30: 1091-1096.
22. Singh G, Triadafilopoulos G (1999). Epidemiology of NSAIDs induced gastrointestinal complications. J Rheumatol 56: 18-24.
23. Suh DC, Woodall BC, Shin SK, Shin SK, Hermes-De Santis ER. (2000). Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 34: 1373-1378.
24. Taylor D, Clark DW, Dovey SM, Tilyard MW. (1994). The prescribing and adverse reactions of non-steroidal anti-inflammatory drugs in general practice. A Dunedin study. NZ Med J 107: 263-266.
25. Uppal R, Jhaj R, Melhotra S. (2000). Adverse drug reactions among inpatients in a north Indian referral hospital. Natl Med J Ind 13: 16-19.
26. Van Puijenbroek EP, Bate A, Leufkens HGM, Linquist M, Orre R, Egberts ACG. (2002). A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11: 3-10.
27. World Health Organization. (1972). International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser 498: 1-25.